Tranilast clinical trials
Tranilast is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Early Phase 1. The sponsor with the most trials is Yifeng Jing (1). The most-studied condition is Prostatic Hypertrophy, Benign.
Where Tranilast is approved
All regulators →- 2 EU orphan designations, most recently for treatment of idiopathic pulmonary fibrosis (22 May 2025, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Tranilast works
All drug targets →- Cryopyrin-associated periodic syndromePhase 2
- GoutPhase 2
- HyperuricemiaPhase 2
- Nasopharyngeal carcinomaPhase 2
- Rheumatoid arthritisPhase 2
- Arthritic joint diseasePhase 1
- Benign prostatic hyperplasiaEarly phase 1
- SarcoidosisEarly phase 1
- Scleredema adultorumEarly phase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL415324, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6326, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Tranilast
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Tranilast
- ChEMBL
- CHEMBL415324
- DrugBank
- DB07615
- PubChem CID
- 5282230
- CAS number
- 53902-12-8
- FDA UNII
- HVF50SMY6E
- Wikidata
- Q2325594
- Wikipedia
- Tranilast
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Tranilast
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia
NCT06689514 · ClinicalTrials.gov ↗ · Prostatic Hypertrophy, Benign
|
Early Phase 1 | Recruiting | Yifeng Jing | China |
|
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
NCT06643689 · ClinicalTrials.gov ↗ · Esophageal Stricture, Esophageal Neoplasms
|
Phase 2 | Not yet open | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tranilast
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Yifeng Jing | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tranilast trials
How many clinical trials are testing Tranilast?
2 current trials in our China register name Tranilast as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Tranilast trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tranilast clinical trials?
Yifeng Jing (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tranilast works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tranilast works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tranilast (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.